Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method

OBJECTIVES: Monetizing health has sparked controversy and has implications for pricing strategies of emerging health technologies. Medical insurance payers typically set up thresholds for quality-adjusted life years (QALY) gains based on health productivity and budget affordability, but they rarely...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Qian, Yin, Yue, Liang, Min, Zhao, Mingye, Shao, Taihang, Tang, Yaqian, Mei, Zhiqing, Li, Hao, Tang, Wenxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621116/
https://www.ncbi.nlm.nih.gov/pubmed/37915053
http://dx.doi.org/10.1186/s12962-023-00487-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621116/
https://www.ncbi.nlm.nih.gov/pubmed/37915053
http://dx.doi.org/10.1186/s12962-023-00487-z

Ejemplares similares